IT, Continence Care and more Copper
BHP, Adyen, MBB, NORMA Group, Coloplast, Bechtle, SIG Group, Eurazeo, Wienerberger, STRATEC, Ströer
At Lux Opes, we break down companies into quick takes that get straight to the point - what is happening, why it matters, and what to watch next. We publish 2-3 times per week, depending on the news flow.
For the best reading experience, we recommend reading at Lux Opes
Financial KPIs
Companies covered in this edition: BHP, Adyen, MBB, NORMA Group, Coloplast, Bechtle, SIG Group, Eurazeo, Wienerberger, STRATEC, Ströer

BHP (BHP Australia): Copper pays the bills, but there is less of it next year
● NEUTRAL
Copper earned 54% of EBITDA in FY26, but FY27 output guidance is 8-16% lower and costs rise.
For the first time, more than half of BHP's earnings came from copper. Underlying EBITDA rose 27% to $32.9bn in the year to June, at a 59% margin, and copper contributed a record $18.2bn, up 48%, or 54% of the group against 45% a year earlier. The realised copper price averaged $5.74/lb, 35% higher, and gold, silver and uranium by-products brought in $4.5bn of revenue, up 45%, which is why copper margins reached 70%.
Western Australia Iron Ore earned $14.7bn, up only 2%, despite record production and shipments. Underlying attributable profit rose 30% to $13.2bn; the reported $9.8bn is after a $2.3bn impairment on the Jansen potash project and $1.1bn for the Samarco dam failure.
The coming year has less copper at a higher cost. Group copper guidance for FY27 is 1,650kt to 1,800kt, 8% to 16% below the 1,953kt just produced. Escondida, the biggest asset, is guided to 1,000kt to 1,100kt from 1,261kt with feed grade around 0.70%, and its unit costs to $1.20 to $1.50/lb from $1.07/lb, before settling at 900kt to 1,000kt a year from FY28 to FY31. In iron ore, unit costs are guided to $20.25 to $21.75 per tonne from $19.66, with diesel the main swing factor. FY27 earnings therefore depend heavily on the copper price holding up. The group is on 7.6x FY27e EV/EBITDA and 17.6x FY27e P/E, against 7.4x FY26 EV/EBITDA, so the rating already leans on that price with no volume growth behind it until the new Escondida concentrator.
The balance sheet improvement owes a lot to one-off money. Free cash flow was $9.8bn, while dividends to BHP shareholders of $6.8bn, payments to minority partners of $2.4bn and $2.0bn for Samarco came to $11.2bn. Net debt still fell to $8.7bn from $12.9bn because BHP received $4.3bn from the Antamina silver streaming deal and $0.8bn from asset sales, and in August a further $2.0bn arrived from Global Infrastructure Partners for a stake in WAIO's inland power. The final dividend is 99 cents, taking the year to $1.72 per share and a 72% payout, the highest in four years. Selling future silver and power cash flows to fund today's payout is a reasonable use of a strong balance sheet, but it cannot be repeated every year.
Copper growth is a long-dated project. Capital and exploration spending is guided at about $11bn in FY27 and FY28. The new Escondida concentrator now carries a capital estimate of $5.4bn to $6.3bn, up from $4.4bn to $5.9bn, for 230kt to 270kt a year of copper, with $0.5bn approved ahead of a final decision in calendar 2027 or 2028. BHP sees its copper output rising about 40% by FY35, and Jansen Stage 1 is 84% complete with first potash due in mid-2027. Until those volumes arrive, BHP is a company with falling copper output in the near term and a large, rising capex bill.
Adyen (ADYEN Netherlands): Volume runs ahead of revenue
● POSITIVE
Revenue grew 21% at constant currency on 24% volume growth; costs rose faster and capex jumps to 7% of revenue.
Adyen processed far more money in the first half and earned a little less on each euro of it. Processed volume rose 24% to €803.8bn, while net revenue grew 19% to €1,302.9m, or 21% at constant currency. Net revenue as a share of volume works out at about 16.2 basis points, down from about 16.9 a year earlier. Part of that is mix: Platforms, the business serving software platforms that embed payments, grew volume 42% to €135.0bn and revenue 37% to €165.5m, but earns about 12.3 basis points. Digital, still 55% of revenue, grew 13% to €719.7m, and Unified Commerce 25% to €417.7m.
The customer base is broadening. About 70% of growth came from existing merchants, and the top 300 accounted for roughly 60% of total growth, down from more than 70% three years ago. New names include Aritzia, OpenAI, Xiaomi and GOV.UK Pay, and the Toast partnership has been extended to the US. The company also launched Adyen Agentic for payments by AI agents and Intelligent Money Movement for payouts and liquidity.
Costs grew faster than revenue. Operating expenses rose 21% to €738.0m, headcount rose by 249 to 5,020, and EBITDA of €641.5m gave a 49% margin, or 50% before €6m of deal costs. Free cash flow was €553.4m, 86% of EBITDA, with capex at 5% of revenue. That capex figure will not last: Adyen is pulling data-centre spending from 2027 into the second half to secure compute and storage and lock in prices, and now expects capex of about 7% of revenue in 2026, falling back towards historical levels afterwards.
Guidance for 2026 is 21% to 23% constant-currency revenue growth including Talon.One, the loyalty software firm bought for €750m, and Orb, a usage-based billing provider bought for $335m, both closed on 1 July. Together they add about a point of growth and take about a point off the margin. The underlying margin should match 2025, and the target of more than 55% by 2028 stays. On 27.1x 2026e P/E and 22.3x 2027e, the rating already assumes most of that margin gain arrives on time. CFO Ethan Tandowsky leaves at the end of August, with Hwa Tsao as interim. We like the breadth of growth, but the 2028 margin target needs several years of revenue growing faster than costs, and this half went the other way.
MBB (MBB Germany): Second-quarter margins far above what the guidance asks for
● POSITIVE
Adjusted EBITDA rose 62% in Q2 at a 25% margin; raised guidance implies a much weaker second half.
MBB had an exceptional second quarter. Revenue rose 4.6% to €298.5m and adjusted EBITDA jumped 61.8% to €75.2m, a 25.1% margin and 8.7 points higher than a year ago. Friedrich Vorwerk, the pipeline and energy infrastructure builder, drove most of it, with smaller gains at DTS, Delignit and Hanke. For the half, revenue slipped 1.7% to €536.0m but adjusted EBITDA rose 53.3% to €117.1m, a 21.8% margin. The first quarter, by subtraction, earned about €41.9m on €237.5m, roughly 17.6%, so the second quarter was a big step up even within the year.
The raised guidance looks conservative against that. MBB now targets an adjusted EBITDA margin of 18% to 20%, up from 15% to 18%, on unchanged revenue of €1.1bn to €1.2bn. That means €198m to €240m of EBITDA for the year, and €81m to €123m in the second half on €564m to €664m of revenue. The implied second-half margin is about 14% to 19%, below the first half and well below the second quarter. Either management expects Vorwerk's project profits to come down from here, or it is leaving itself plenty of room. Net income for the half rose to €23.9m from €14.7m.
The cash pile keeps growing. Group net liquidity was €769.0m at the end of June, of which €431.9m sits at the holding company, up from €373.6m at the end of 2025. Holding cash rose by about €58m in six months, and how MBB deploys it will matter as much for shareholders as this year's margins.
On 13 August MBB sold CT Formpolster, its smallest company, to Nexeras, a succession vehicle backed by Constantin Mang and Christian Theurer. Mang was MBB's CEO from 2021 to 2025, and the sale came at Nexeras' initiative. No price was disclosed. The deal is too small to matter for the numbers, but a sale to a former chief executive is exactly the kind of transaction where shareholders should see the terms, and we would have liked them in the announcement.
NORMA Group (NOEJ Germany): Handing back almost a third of the company
● POSITIVE
A €208m tender for up to 29% of the share capital completes the €260m return; the remaining business earns thin margins.
NORMA Group is finishing the cash return from the sale of its Water Management business with a large tender. The company offers to buy back up to 9,306,487 shares at €22.35 each, about €208m, equal to 29.21% of the share capital and 32.45% of the shares outstanding excluding treasury stock. The acceptance period runs from 17 August to 15 September, and all shares bought will be cancelled. Together with the roughly €53m buyback completed in the spring, it completes the capital return of about €260m announced in February. The price sits within the value ranges of an independent IDW S1 valuation dated 13 August.
The mechanics are designed to treat small holders fairly. Each share carries one tender right, 19 rights allow the tender of 6 shares, and the rights trade on the Frankfurt exchange from 20 August to 10 September, so holders who do not want to tender can sell them. Shares can also be offered in a residual allocation if the maximum is not reached. The CEO, a second board member and the chair of the supervisory board will not tender but plan to sell their rights. Using the company's own ratios, NORMA has about 31.9m shares in issue and 28.7m outstanding, and full take-up would leave about 19.4m.
The balance sheet can carry it. NORMA had net cash of €303.9m at the end of June, so after the €208m outflow about €96m would remain. The continuing business, though, earns little. Second-quarter sales were €211.8m, flat in constant currency, and adjusted EBIT rose to €7.6m, a 3.6% margin against 1.1% a year earlier, on lower material costs and cuts in personnel and overheads. Industry Applications grew 8.4% in constant currency to €70.6m, with new orders from data centres, battery storage and energy infrastructure, while Mobility & New Energy fell 3.7% to €141.3m with weak European and Chinese car production. Guidance for 2026 is sales growth of 0% to 2%, an adjusted EBIT margin of 2% to 4% and net operating cash flow of only €10m to €20m.
Returning the money is the right call for a business that generates so little cash, and a much smaller share count gives each remaining share a larger claim on any recovery. On the table the €660m market cap carries an EV of only €154m, 2.8x 2026e EV/EBITDA, yet 56.3x 2026e P/E, so very little of that EBITDA reaches net profit. That recovery has to come from margins. The strategy update on 19 October is where NORMA needs to show how a 3% to 4% margin becomes something worth owning.
Coloplast (COLOB Denmark): A steady quarter, a new CEO and a Kerecis write-down
● NEUTRAL
Q3 organic growth was 6% and guidance held; Kerecis fell 6% and carries a DKK 3bn impairment.
Coloplast's chronic care business delivered again in the third quarter, and the acquired wound biologics business did not. Organic growth was 6% and reported revenue in kroner also rose 6%, as currencies netted out. EBIT before special items was DKK 1,929m, 5% higher in constant currencies but only 1% higher as reported, and the margin fell to 26% from 28%. About 110 basis points of that came from currency and about 60 from Kerecis.
The core held up well. Continence Care grew 8%, with double-digit growth in the US and the Luja catheter driving Europe. Ostomy Care grew 5%, with strong double-digit growth in the US and solid growth in Europe and in emerging markets outside China. Interventional Urology grew 7% on the US men's health business, and Voice & Respiratory Care 6%, with laryngectomy strong and tracheostomy softer. Wound & Tissue Repair grew only 3%: advanced dressings rose 4%, helped by order phasing in Germany and the Middle East but hurt by a product return in China, while Biologics, mainly Kerecis, fell 6% after a reimbursement change and ran at a minus 5% EBIT margin before purchase price amortisation.
Over nine months organic growth was 6%, EBIT before special items was DKK 5,599m, up 5% in constant currency, and adjusted diluted earnings per share rose 14%, helped by currency gains in the financial line. Free cash flow reached 20% of sales against 16%. Guidance is unchanged at 5% to 6% organic growth, around 5% constant-currency EBIT growth and about 3% reported growth. Kerecis is now expected to grow about 0% at about a 0% margin, and special items of about DKK 3.1bn include a DKK 3bn impairment on it. Nine months at 5% EBIT growth already match the full-year guide, so the fourth quarter only has to hold the pace.
Gavin Wood presented his priorities after his first 100 days as CEO, singling out chronic care and the untapped potential in the US. That fits the numbers: the old franchises in ostomy and continence are growing well, US growth is double digit in both, and the business bought to add growth is being written down. The DKK 3bn impairment puts that on the record. We see Coloplast as a solid chronic care company again, with Kerecis now a small drag.
Bechtle (BC8 Germany): Double-digit growth with fewer people
● NEUTRAL
Business volume rose 18% in Q2, 12.9% organically, with organic headcount down 1.4%; guidance raised.
Bechtle grew fast in the second quarter while shrinking its organic workforce. Business volume rose 18.1% to €2.3bn and revenue 16.5% to €1.7bn. Organically, business volume grew 12.9% and revenue 10.3%, so acquisitions in Spain, Italy and Portugal added about five points. Earnings before tax rose 20.1% to €80.2m, a stable 3.5% of business volume and 4.6% of revenue. Germany, France and Benelux each grew business volume by more than 10% organically, and the Other Europe segment by more than 20%, with business and public-sector customers both contributing. Staff numbers went the other way. Headcount was 16,418 at the end of June, 5.2% higher, but all of the increase came from acquisitions, and organically the workforce shrank 1.4% and fell by 78 people even against the first quarter. Growing organic business volume by 12.9% with 1.4% fewer people is a strong operating result, and it explains why profit grew faster than volume.
Cash was weak, for a reason. Operating cash flow was minus €101.7m in the half against plus €24.2m a year earlier, because growth was concentrated at the end of the quarter and Bechtle built up inventory backed by customer orders. Days sales outstanding fell further and working capital dropped to 6.8% of annualised business volume from 7.3%, so the outflow looks like timing, and the company expects firmly positive operating cash flow for the year. The CEO also names a memory crisis among the difficult conditions the company has had to manage this year.
The order backlog reached a record €3.5bn, and guidance went up sharply: business volume growth of more than 10%, from 5% to 10%, and revenue and EBT growth of 5% to 10%, from 0% to 5%. On 2025 revenue of €6.41bn, that points to roughly €6.7bn to €7.1bn this year. With a record backlog and five points of growth already coming from acquisitions, the new targets look achievable. The second half has to turn the inventory into cash, and that is the one part of this report we would want confirmed.
SIG Group (SIGN Switzerland): Back to the interim CEO
● NEUTRAL
CEO Mikko Keto leaves after months; CFO Ann-Kristin Erkens takes both jobs ahead of the 27 October CMD.
SIG has changed chief executive for the second time in a year. On 17 August the board appointed CFO Ann-Kristin Erkens as CEO with immediate effect, replacing Mikko Keto, who joined in the spring. Erkens ran the company as interim CEO from August 2025 to the end of February 2026 and will remain CFO until a successor is found. The board's explanation is that continuity of leadership and pace of execution now matter most, and that Erkens, who shaped the performance improvement roadmap, is best placed to deliver it. She joined SIG as CFO in November 2023 after more than 20 years in finance, operations and strategy roles at Henkel.
The timing is odd, because the business is doing reasonably well. Keto presented the half-year results on 28 July. Revenue rose 0.8% at constant currency, or 0.4% also excluding resin price effects. Adjusted EBIT rose to €243.7m and the margin to 15.6% from 14.8%, helped by efficiency measures started in the fourth quarter of 2025, surcharges to pass on raw material costs and lower depreciation after the 2025 impairments. Overheads fell to 11.3% of revenue from 11.9%. Free cash flow was minus €32.2m, €107.6m better than a year earlier, and net leverage stayed at 3.0x. Europe shrank 3.1% as ambient juice contracted and customers took part in fewer UHT milk retail tenders, while the Americas grew 2.9%, Asia Pacific 2.4% and IMEA 0.3%, with 13 new fillers won there. SIG Terra, the aluminium-free carton, grew volumes 25%.
Guidance for 2026 is unchanged at 0% to 2% revenue growth and an adjusted EBIT margin of 15.7% to 16.2%, so the second half needs a margin at least as high as the first. The bigger exposure is governance. One person now holds both the CEO and CFO roles at a company carrying 3.0x leverage, after two abrupt changes at the top. The capital markets day on 27 October, where Erkens and the team will present the strategy and medium-term targets, has to show a plan that the board is willing to stick with, and a permanent CFO appointment would help more than any target.
Eurazeo (RF France): The portfolio stops shrinking, buybacks do the rest
● NEUTRAL
NAV per share rose 3.3%, mostly from buybacks; two exits at 150% above book support the marks.
Eurazeo's portfolio created value again in the first half, though only just. Net portfolio value per share rose 3.3% to €105.4 from €102.1, but organic value creation contributed only 0.3%, or €20m, against minus 0.7% in the second half of 2025 and minus 3.5% in the first half. Share buybacks added 2%, as the share count fell from 66.8m to 65.5m, and scope and other effects 1.0%. Net income attributable to the group was minus €6m, against minus €311m a year earlier.
The marks look more credible than they did. Buyout holdings rose 0.2% in value while their revenue grew 4% and EBITDA 7%, with Capital up 0.7%, Elevate up 1.8%, Brands down 2.2% and Secondaries down 9.9%. Growth assets rose 1.0% on revenue growth of 22%. Eurazeo says it is still cutting some sector multiples, SaaS among them. The best evidence comes from exits: Fermax was sold at 2.6 times cost with an IRR close to 40%, and Ex Nihilo at 2.7 times, both at a price 150% above their last valuation. FST Hotels went at book. Balance sheet disposals announced in the half came to €0.3bn, 4.3% of the end-2025 portfolio, of which €140m was cash in. Several processes are running and management promises substantial exit volume this year, which is what the second half has to prove.
The asset management side keeps growing. Assets under management rose 9% to €40bn, with third-party money up 13% to €31.1bn, and fee-paying assets reached €29.4bn. Fundraising was €2.3bn, of which €1.5bn in private debt, where the EPD VII direct lending fund closed at €3.9bn against a €3.0bn target. Management fees were €213m and asset management EBITDA rose 20% to €100m, a 44.7% margin. Balance sheet money is now 22% of assets under management, down from 31% at the end of 2023.
Shareholder returns are the other lever. The dividend rose 10% to €2.92, about 2% of the shares were bought back in the half for €58m, and the 2026 program covers about 4% for about €120m, followed by about 9% in 2027, for roughly 25% cumulatively over 2024 to 2027. With per-share value growth coming mainly from buybacks, the exit program decides whether the portfolio can carry its share of the return, and the two exits above book are a good start.
Wienerberger (WIE Austria): The housing recovery that did not come
● NEGATIVE
Guidance cut to €700m operating EBITDA as new-build stays weak; net debt rose to €2.4bn and the CEO left.
Wienerberger planned for a recovery in new housing this year, and it has not happened. The company now expects operating EBITDA of €700m, about 7% below the roughly €754m of 2025, because residential new-build activity is expected to stay subdued. Management puts the hit at about €100m against the assumptions behind the initial guidance, of which about €40m was already felt in the first half, so the second half carries the other €60m.
The second quarter shows the pattern. Revenue rose 13% to €1.4bn, with 7% organic growth and 6% from acquisitions, but operating EBITDA fell to €230m from €253m and the margin to 16.3% from 20.3%. Profit after tax dropped to €31m from €103m. New-build demand was weakest in the United States, Canada and the UK, where financing costs keep developers and homeowners away, and Germany and France also fell short. Central and Eastern Europe improved, with Poland and the Czech Republic picking up. Cost inflation linked to geopolitical conflicts added to the pressure, and in North American infrastructure the company reports highly competitive pricing.
The portfolio shift is real. Infrastructure and renovation now make up more than 60% of revenue after the majority stake in Italcer, the Italian tile maker, in April, the NEWS wastewater business in Sweden and Terreal in 2024. Roofing benefits from renovation of old housing stock, and pipes from water and power grid investment. But acquisitions add revenue while the margin falls, and they add debt: net debt was €2.4bn at the end of June against €2.0bn a year earlier, about 3.4 times this year's guided EBITDA. Equity is c.47% of a €4.6bn EV, and the multiple has gone up to 6.7x 2026e EV/EBITDA from 5.9x on 2025 as EBITDA falls, so the equity carries most of the risk of a slower new-build recovery. Free cash flow in the quarter fell to €83m from €124m as Italcer increased working capital. A US subsidiary also agreed to pay $52.4m to settle three antitrust class actions, which will hit reported EBITDA this year.
The company is doing all this without its long-time leader. Heimo Scheuch stepped down for health reasons on 10 August after more than 17 years as CEO, and Gerhard Hanke, COO for Central and East, is interim CEO while a search runs. Rising leverage, a falling margin and an open CEO seat make this a period to wait for evidence that new-build volumes have bottomed, and the guidance itself says they will stay subdued over the coming quarters.
STRATEC (SBS Germany): A better quarter, and the year still hangs on December
● NEUTRAL
Q2 adjusted EBIT margin recovered to 11.9%, but consumables fell 12% and growth depends on year-end orders.
STRATEC's second quarter was much better than its first, but the year still depends on a few weeks in December. Sales rose 2.4% at constant currency to €59.1m in the quarter, and adjusted EBIT more than doubled to €7.0m, an 11.9% margin against 5.4% a year earlier. The first quarter, by difference, earned only about €0.7m on €53.4m of sales. For the half, sales fell 3.3% at constant currency to €112.5m and the adjusted EBIT margin was 6.9% against 7.2%. Operating cash flow swung to €29.7m from minus €5.8m as receivables from last year's strong year-end were collected.
The mix moved towards equipment. Analyzer Systems grew 15.4% at constant currency to €39.7m, with demand in immunodiagnostics, molecular diagnostics and immunohematology, while veterinary diagnostics and the Diatron products fell. Service Parts and Consumables dropped 11.9% to €46.1m, and Development and Services 7.8% to €26.2m. Systems now make up 35% of sales against 29% a year earlier, and consumables 41% against 45%. The reason for the consumables decline matters more than its size. STRATEC says customers whose ownership has changed are cutting service costs and stock to raise capital efficiency. That is a decision by the customer's new owners, and it can persist well beyond a single destocking cycle.
Guidance is unchanged: sales growth at constant currency of a mid to high single-digit rate and an adjusted EBIT margin around last year's 10.0%, with the growth to come almost entirely from very strong year-end business. Management says order patterns are subject to highly elevated volatility. After a 3.3% decline in the first half, the second half has to grow well above the full-year rate, so a slip of a few large system deliveries into January would change the year. Capex is planned at 6.5% to 8.5% of sales.
The medium term rests on new systems being transferred to series production, with partner launches scheduled for mid-2027, an existing research platform being adapted for diagnostic use, and growing demand for lifecycle and cybersecurity work as FDA requirements tighten. Headcount fell 2.3% to 1,383. The second quarter shows the cost base can earn double-digit margins at modest volumes. We would want to see consumables stop falling before reading the systems growth as a stronger base for future recurring revenue.
Ströer (SAX Germany): Outdoor grows, the rest gets smaller
● NEUTRAL
Out-of-Home grew 10.3% in Q2 on digital screens, but group EBITDA guidance stays flat as other units drag.
Ströer's outdoor business is growing much faster than German advertising as a whole. Out-of-Home Media revenue rose 10.3% to €270.5m in the second quarter, with digital screens up 24.3% while classic posters slipped 1.3%. The German advertising market grew only 1.9% in the quarter on gross Nielsen figures, and the World Cup brought additional bookings. Group revenue reached €541.8m against €504.7m and adjusted EBITDA €153.8m against €140.9m. Outdoor now brings in half of group revenue.
The other two segments pull in different directions. Digital & Dialog Media grew 14.4% to €476m in the half, but the fastest part is the labour-heavy call centre business, which grew by about a quarter, so the segment margin fell noticeably. DaaS & E-Commerce shrank to €156m from €176m, an 11% drop. At AsamBeauty the core TV shopping audience is ageing and cosmetics demand is weaker, and Statista is moving towards B2B subscriptions, a change Ströer says will take time for clients to adopt. With the sale of Statista's consulting business, the segment's revenue should fall at a low double-digit rate in the third quarter.
For the half, organic revenue grew 2.7% to €1.037bn and adjusted EBITDA 3% to €273m, while second-quarter net income fell 8% to €29.7m on a weaker financial result and special items. The outlook is unchanged: low to mid single-digit organic revenue growth and broadly stable adjusted EBITDA for the year, with mid single-digit growth in outdoor in the third quarter. Stable group EBITDA while outdoor grows by double digits means the rest of the group is taking away much of what outdoor adds.
Ströer's AI booking platform, Ad Manager, has gone live in a first test, but a broader rollout is not expected before the end of 2027, and management declined to comment on the reports of takeover interest. The obvious way to show what the outdoor business earns is to separate it from the parts that are shrinking or dilutive. Until that happens, investors get a high-quality advertising asset bundled with a call centre operation and two declining online businesses.